John S. Yu, MD
CEO & Chairman
- Professor and Clinical Chief of Neurosurgery, Director of the Brain Tumor Center at Cedars Sinai Medical Center.
- Developed numerous immunotherapies and nanotechnologies from his NIH funded laboratory.
- Developed 8 new investigational drugs with the FDA and has led numerous clinical trials.
- Former officer of ImmunoCellular Therapeutics.
- BAS from Stanford, MD from Harvard Medical School and MIT.
- Immunology Fellowship at the Institut Pasteur, Paris, Neurosurgery Residency at Massachusetts General Hospital/Harvard.
Ramachandran Murali, Ph.D
VP, Research and Development
- Associate Professor, Biomedical Sciences and Research in Immunology at Penn/Cedars Sinai Medical Center.
- Leading expert in X-ray crystallography, biophysical, biochemical, and immunology fields, having made significant advances in molecular engineering and cell surface receptors by developing pharmacological agents which include new paradigms in structure-based peptidomimetics drug discovery.
- Developed numerous technologies that reverse key mechanisms of immune suppression of cancer.
Neil Bhowmick, Ph.D
Chief Scientific Officer
- Professor of the Department of Medicine and Director of the Cancer Biology Program at Cedars-Sinai Medical Center.
- Fellowship at Vanderbilt University Medical Center Research Director, Oppenheimer Urologic Reference Laboratory (OURLab).
- Holds 6 patents for biomarker detection platforms and stromal targeted therapeutics (inclusive of ENV105 and ENV205).
- Consultant at Xencor Inc. (NASDAQ: XNCR) and Tracon Pharma (NASDAQ: TCON).
- NCI/NIH funded for over 15 years and cited over 11,700 times.
Doug Samuelson
Chief Financial Officer
- Finance & accounting professional with over 25 years of experience.
- Certified Accountant and current CFO of Wellness Center, USA Inc.
- Held numerous former CFO positions including Second Sight Medical Products, Inc., AdvaVet, Inc. and Solis Tek, Inc.
- MSc, Computer Science from California State University, BSc, Accounting from University of Utah.
John S. Yu, MD
CEO & Chairman
- Professor and Clinical Chief of Neurosurgery, Director of the Brain Tumor Center at Cedars Sinai Medical Center.
- Developed numerous immunotherapies and nanotechnologies from his NIH funded laboratory.
- Developed 8 new investigational drugs with the FDA and has led numerous clinical trials.
- Former officer of ImmunoCellular Therapeutics.
- BAS from Stanford, MD from Harvard Medical School and MIT.
- Immunology Fellowship at the Institut Pasteur, Paris, Neurosurgery Residency at Massachusetts General Hospital/Harvard.
Ramachandran Murali, Ph.D
VP, Research and Development
- Associate Professor, Biomedical Sciences and Research in Immunology at Penn/Cedars Sinai Medical Center.
- Leading expert in X-ray crystallography, biophysical, biochemical, and immunology fields, having made significant advances in molecular engineering and cell surface receptors by developing pharmacological agents which include new paradigms in structure-based peptidomimetics drug discovery.
- Developed numerous technologies that reverse key mechanisms of immune suppression of cancer.
Neil Bhowmick, Ph.D
Chief Scientific Officer
- Professor of the Department of Medicine and Director of the Cancer Biology Program at Cedars-Sinai Medical Center.
- Fellowship at Vanderbilt University Medical Center Research Director, Oppenheimer Urologic Reference Laboratory (OURLab).
- Holds 6 patents for biomarker detection platforms and stromal targeted therapeutics (inclusive of ENV105 and ENV205).
- Consultant at Xencor Inc. (NASDAQ: XNCR) and Tracon Pharma (NASDAQ: TCON).
- NCI/NIH funded for over 15 years and cited over 11,700 times.
Doug Samuelson
Chief Financial Officer
- Finance & accounting professional with over 25 years of experience.
- Certified Accountant and current CFO of Wellness Center, USA Inc.
- Held numerous former CFO positions including Second Sight Medical Products, Inc., AdvaVet, Inc. and Solis Tek, Inc.
- MSc, Computer Science from California State University, BSc, Accounting from University of Utah.
